About
Innocan Pharma is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation.
In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales.
Funding history · 9 rounds · $23.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did InnoCan Pharma launch trading on the OTCQB Venture Market?
- InnoCan Pharma launched trading on the OTCQB Venture Market in August 2021.
- What significant agreement did InnoCan Pharma announce in December 2021 regarding its CLX platform?
- In December 2021, InnoCan Pharma announced the execution of a Research & License Agreement with Ramot, Tel Aviv University's technology transfer company, for its Cannabinoids Loaded Exosome Delivery Platform (CLX).
- What was the outcome of InnoCan Pharma's cosmetic clinical study for its SHIR(TM) Premium CBD Facial Serum in October 2020?
- In October 2020, InnoCan Pharma's cosmetic clinical study indicated a 90% wrinkle reduction after using its SHIR(TM) Premium CBD Facial Serum.
- What was a key development for InnoCan Pharma's LPT CBD-loaded liposome platform in June 2021?
- In June 2021, InnoCan Pharma's Liposome Platform Technology demonstrated a 7-week prolonged release of CBD into the bloodstream in an animal study.
- When did InnoCan Pharma complete its trademark registration in the EU, UK, and Switzerland?
- InnoCan Pharma completed its trademark registration in the EU, UK, and Switzerland in December 2020.
- What was a notable financial result for InnoCan Pharma in Q3 2022?
- In Q3 2022, InnoCan Pharma reported a 700% increase in revenues compared to Q3 2021.
- What was the outcome of InnoCan Pharma's pre-clinical trial of a Liposomal-CBD Injection on a paralyzed goat in May 2023?
- In May 2023, InnoCan Pharma reported success in a pre-clinical trial where a Liposomal-CBD Injection was administered to a paralyzed goat.
- What significant regulatory step did InnoCan Pharma initiate in April 2024?
- In April 2024, InnoCan Pharma initiated the FDA approval process for its Liposome Injection Therapy for Chronic Pain.
- What was the revenue reported by InnoCan Pharma for the full year 2024?
- InnoCan Pharma reported full year 2024 revenues of US $29.4 million, more than doubling from the previous year.